U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H19NO3
Molecular Weight 237.2949
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VILOXAZINE

SMILES

CCOC1=C(OCC2CNCCO2)C=CC=C1

InChI

InChIKey=YWPHCCPCQOJSGZ-UHFFFAOYSA-N
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

HIDE SMILES / InChI

Molecular Formula C13H19NO3
Molecular Weight 237.2949
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Viloxazine is an antidepressant drug was used to treat patients with depression. Viloxazine inhibits noradrenaline uptake. This drug was approved in some Europe countries, but not in the USA, but then it was discontinued because of competition from other drugs. In the frame of drug repositioning, Viloxazine participated in clinical trials for the treatment of attention deficit hyperactivity disorder. Phase II of trials was successfully passed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
[Comparative evaluation of the therapeutic efficacy of the antidepressants adepren, linamiphen and emovit].
1986
Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.
2002
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
2002
Tricyclic and related drugs for nocturnal enuresis in children.
2003
A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs.
2003 Oct
Contribution of sleep research to the development of new antidepressants.
2005
The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.
2005
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
2005 Dec 9
Internet-based search of randomised trials relevant to mental health originating in the Arab world.
2005 Jul 26
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach.
2006 Oct 20
Narcolepsy: current treatment options and future approaches.
2008 Jun
A prognostic system applicable to patients with resectable liver metastasis from colorectal carcinoma staged by positron emission tomography with [18F]fluoro-2-deoxy-D-glucose: role of primary tumor variables.
2008 May
Adjustment Disorder: epidemiology, diagnosis and treatment.
2009 Jun 26
Getting the balance right: Established and emerging therapies for major depressive disorders.
2010 Sep 7
Patents

Patents

Sample Use Guides

100 mg
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:09:32 UTC 2023
Edited
by admin
on Thu Jul 06 00:09:32 UTC 2023
Record UNII
5I5Y2789ZF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VILOXAZINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
viloxazine [INN]
Common Name English
Viloxazine [WHO-DD]
Common Name English
VILOXAZINE [MI]
Common Name English
MORPHOLINE, 2-((2-ETHOXYPHENOXY)METHYL)-
Systematic Name English
(±)-2-(O-ETHOXYPHENOXYMETHYL)MORPHOLINE
Common Name English
VILOXAZIN
Common Name English
VILOXAZINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06AX09
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
WHO-VATC QN06AX09
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
WIKIPEDIA Designer-drugs-Viloxazine
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
NCI_THESAURUS C265
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
Code System Code Type Description
DAILYMED
5I5Y2789ZF
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
FDA UNII
5I5Y2789ZF
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
MERCK INDEX
M11448
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY Merck Index
INN
3489
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
DRUG BANK
DB09185
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
ChEMBL
CHEMBL306700
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
WIKIPEDIA
VILOXAZINE
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
ECHA (EC/EINECS)
256-281-7
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID6057900
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
MESH
D014745
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
CAS
46817-91-8
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
RXCUI
11196
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY RxNorm
DRUG CENTRAL
2820
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
PUBCHEM
5666
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
SMS_ID
100000079104
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
EVMPD
SUB00049MIG
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
NCI_THESAURUS
C152877
Created by admin on Thu Jul 06 00:09:32 UTC 2023 , Edited by admin on Thu Jul 06 00:09:32 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE
ENANTIOMER -> RACEMATE
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE
METABOLIC ENZYME -> SUBSTRATE
EXCRETED UNCHANGED
BINDER->LIGAND
Viloxazine is 76-82% bound to human plasma proteins over the blood concentration range of 0.5 mcg/mL to 10 mcg/mL.
BINDING
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
Converted to glucuronide
MAJOR
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC